Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2296 to 2310 of 8221 results

  1. Infrared lasers for treating onychomycosis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Intradiscal oxygen-ozone treatment of symptomatic lumbar disc herniation

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Transoral Endoscopic Thyroid/Parathyroid Vestibular Approach

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  4. Extra-vascular implantable cardioverter defibrillator (EVICD) for people with a defibrillator

    Awaiting development Reference number: GID-IPG10437 Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  5. Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]

    In development Reference number: GID-TA11675 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Artificial Intelligence in MRI for prostate cancer diagnosis

    Awaiting development Reference number: GID-HTE10089 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  7. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy ID6575

    In development Reference number: GID-TA11742 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]

    In development Reference number: GID-TA10904 Expected publication date:  03 December 2025

    Technology appraisal guidance
    In development

  9. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development Reference number: GID-TA11340 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date:  30 September 2026

    Technology appraisal guidance
    In development

  11. Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 [TSID11827]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656]

    Awaiting development Reference number: GID-TA11871 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]

    In development Reference number: GID-TA11766 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years ID6537

    In development Reference number: GID-TA11636 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  15. Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]

    In development Reference number: GID-TA11576 Expected publication date:  18 June 2026

    Technology appraisal guidance
    In development